Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Shareholder Terry Smith labels Unilever's GSK bid "near death experience"

Published 20/01/2022, 16:04
Updated 20/01/2022, 16:07
© Reuters. FILE PHOTO: A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019.  REUTERS/Peter Nicholls

By Siddharth Cavale

(Reuters) - Influential British fund manager Terry Smith attacked Unilever (LON:ULVR)'s failed 50 billion pound ($68.2 billion) bid for GSK's Consumer Health assets as a "near death experience" and urged Unilever management to focus on strengthening performance.

In a letter to investors of his Fundsmith vehicle, now the 13th biggest Unilever shareholder, Smith criticized Unilever for failing to openly communicate the benefits of the deal and its "penchant for corporate gobbledegook as substitute for effective action."

"It seems to us that Unilever management's response to its poor performance has been to utter meaningless platitudes to which it has now attempted to add major M&A activity. What could possibly go wrong?," said the letter, signed by Smith and head of research, Julian Robins.

Unilever did not immediately respond to a request for comment.

Late on Wednesday, Unilever effectively abandoned its offer for GlaxoSmithKline's Consumer Health unit, after the deal was widely panned by the market and analysts.

GSK had said the bid undervalued the business and that it would go ahead with its plan to spin it off instead.

"We are pleased that the Unilever management listened and has seemingly ended the attempt to acquire GSK Consumer by refusing to up its bid for a fourth time," the letter said, describing its critique as a post-mortem into a "near death experience" in the form of the failed approach.

Smith's "near death experience" phrase echoed comments made by Unilever's previous CEO Paul Polman when describing his successful fight against a hostile takeover bid by Kraft Heinz (NASDAQ:KHC) in 2017.

Having rejected the bid, GSK's consumer business would face its own reckoning when it is listed as a separate company later this year, the Fundsmith letter added.

This isn't Smith's first recent attack on Unilever.

© Reuters. FILE PHOTO: A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019.  REUTERS/Peter Nicholls

Last week, he criticised Unilever for being "obsessed" with sustainability at the expense of performance, after the stock featured among its equity fund's bottom-5 performers in 2021.

($1 = 0.7332 pounds)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.